Sofinnova Ventures
Actively deployingMenlo Park · Series A–Series B · 43 people tracked
Investment thesis
Sofinnova is a healthcare investment firm that focuses on improving patient outcomes through life science innovations. The firm invests in both private and public equity companies, with a primary concentration on therapeutic drug development. Their mission centers on delivering value for patients, entrepreneurs, and investors through science-driven investment decisions.
Source: firm website, verified Jul 20, 2026.
Team · 43 people
from the firm's websiteWhat they invest in
from 43 of 193 portfolio companiesBiotech ×41Medical Devices ×30Healthtech ×24Digital Health ×8AI & Machine Learning ×1Consumer ×1Deep Tech ×1FemTech ×1
HQs:United States×25Denmark×2France×1United Kingdom×1Netherlands×1Vietnam×1
Investments · showing 60 of 193
founders shown can be your intro pathAclaris develops investigational monoclonal antibodies and small-molecule inhibitors targeting immune pathways for the treatment of atopic, autoimmune, and respiratory diseases. The company's clinical and preclinical pipeline includes candidates in development for severe asthma, atopic dermatitis, and T-cell-mediated autoimmune conditions.
BiotechHealthtechMedical Devices
Aeovian Pharmaceuticals is a clinical-stage biopharmaceutical company developing selective small molecule inhibitors to treat rare genetic and age-related diseases caused by dysregulated cellular metabolism. The company's lead candidate, AV078, is a CNS-penetrant mTORC1 inhibitor in development for tuberous sclerosis complex refractory epilepsy.
Biotech
Allison J. Hulme(CEO & President)John Kincaid(Chief Scientific Officer)Richard Gaster(Director & Chairman)
Aerie Pharmaceuticals develops ophthalmic pharmaceutical products including Rocklatan and Rhopressa for glaucoma and ocular hypertension, and AR-15512 for dry eye disease. The company serves eye care professionals and patients in the global ophthalmic pharmaceutical market.
BiotechHealthtechMedical Devices
Jade Biosciences is a clinical-stage company developing therapies that target autoimmune diseases. Its lead candidate, JADE101, inhibits the cytokine APRIL for the treatment of immunoglobulin A nephropathy.
BiotechHealthtech
AFYX is a biopharmaceutical company focused on reformulation and repurposing of existing pharmaceuticals for conditions including head and neck cancer, labor induction, cluster headaches, and pain and addiction. The company operates across 46 global markets through direct operations and partnerships.
BiotechHealthtechMedical DevicesHørsholm, DK
Dr. Claus J. Møller-San Pedro(CEO)
ANI Pharmaceuticals develops pharmaceutical treatments focused on rare diseases. The company serves patients requiring specialized medical interventions.
BiotechHealthtechMedical Devices
Alkeus Pharma develops therapies for retinal diseases, including inherited and neovascular conditions. The company focuses on gene therapies and other advanced treatment modalities for ophthalmology.
BiotechDigital HealthHealthtechMedical DevicesCambridge, US
Carlos Quezada-Ruiz(Chief Medical Officer)
Amarin Corporation is a cardiovascular health pharmaceutical company developing treatments to prevent cardiovascular disease. The company focuses on pharmaceutical development and clinical research in the cardiovascular health sector.
BiotechHealthtechMedical Devices<UNKNOWN>, US
Anesiva is a biopharmaceutical company developing Nexletol for diet management.
Biotech
Anthera produces makeup and skincare products made in France with natural, non-toxic ingredients that are cruelty-free and vegan. The brand focuses on combining cosmetic aesthetics with daily skincare benefits for consumers seeking clean beauty products.
ConsumerWellness & FitnessFrance, FR
Antiva Biosciences develops a topical therapeutic for women with high-risk HPV infection and pre-cancerous cervical lesions, utilizing antiviral prodrug chemistry. The company targets an unmet clinical need where no approved therapeutic options currently exist.
BiotechFemTechHealthtechMedical Devices
Ascendis Pharma is a biopharmaceutical company developing therapies for hormone-related disorders and rare diseases. The company focuses on long-acting therapeutic formulations to address endocrine and rare disease indications.
BiotechHealthtechMedical DevicesDenmark, DK
Jan Møller Mikkelsen(Founder, President and Chief Executive Officer)
aTyr is a clinical-stage biotechnology company developing therapies derived from tRNA synthetase biology to treat fibrosis and inflammation, with its lead candidate efzofitimod in clinical trials for interstitial lung disease. The company leverages a proprietary discovery platform targeting immune-mediated disorders in pulmonary and systemic conditions.
BiotechHealthtechMedical Devices
BIOAGE develops therapies targeting the molecular pathways that drive aging to increase healthspan and address age-related chronic diseases. The company uses data-driven approaches and bioinformatics to identify and develop its pipeline of aging-focused therapeutics.
BiotechHealthtechLongevity
Kristen Fortney, PhD(Co-Founder, CEO)Eric Morgen, MD(Co-Founder, COO)
AbbVie is a biopharmaceutical company that discovers and delivers medicines for immune-mediated diseases and other therapeutic areas globally.
BiotechHealthtechMedical Devices
City Therapeutics develops RNAi-based medicines targeting rare, specialty, and prevalent diseases using engineered trigger molecules and precision delivery ligands. The company aims to expand RNAi therapeutics beyond liver targeting to additional cell and tissue types.
BiotechMedical DevicesCambridge, US
Mark Keating, MD(Co-founder)Kotaro Nakanishi, PhD(Co-founder)Yukihide Tomari, PhD(Co-founder)Phillip Zamore, PhD(Co-founder)
Coherus Oncology develops and commercializes immuno-oncology therapies, including the approved LOQTORZI, to treat patients with cancer. The company focuses on expanding its pipeline of clinical-stage candidates targeting the tumor microenvironment.
BiotechHealthtechMedical Devices
Board seats · per SEC filings · 11
what is this? ⓘ$89.1M raise · filed Jun 2026 · via Maha Katabi
$21.5M raise · filed Dec 2025 · via David P. Kabakoff
$125M raise · filed Oct 2025 · via Maha Katabi
$150M raise · filed Apr 2025 · via Chris Carpenter
$226M raise · filed Oct 2024 · via James I. Healy
$160.4M raise · filed Jun 2024 · via Maha Katabi
$35.7M raise · filed Jul 2023 · via David J. Kabakoff
$167.9M raise · filed Sep 2022 · via Maha Katabi
$31M raise · filed Nov 2021 · via David Kabakoff
$70.7M raise · filed Feb 2021 · via Maha Katabi
$75.8M raise · filed Aug 2020 · via Jonathan T. Leff, Maha T. Katabi
Inferred from directors named on each company's SEC Form D — public regulatory data, not a portfolio list published by the firm.
Frequently asked questions
- What stage does Sofinnova Ventures invest at?
- Sofinnova Ventures invests at the Series A, Series B stages.
- What sectors does Sofinnova Ventures focus on?
- Sofinnova Ventures focuses on Biotech, Healthtech, Medical Devices.
- Where is Sofinnova Ventures located?
- Sofinnova Ventures is headquartered in Menlo Park, US.
Similar investors
Breyer Capital invests in breakthrough biomedical technologies, emerging models of care, and economic systems that drive sustainable healthcare transformation. The firm partners early and deeply with entrepreneurs across AI-first diagnostics, programmable medicines, data infrastructure, financial systems, clinician software, and novel care delivery models.
Data Collective identifies and supports ambitious company founders developing technology-driven solutions. The firm focuses on companies using innovation to restore predictability in an unstable world, with demonstrated expertise across clean energy, gene therapy, sustainable agriculture, and machine learning applications in healthcare.
Google Ventures invests in innovative founders across diverse industries, focusing on companies where they can provide value across multiple stages and milestones through long-term relationships.
Innovestor is a Nordic investment group active across early-stage platforms including Angel CoFund, Life Science Fund, and Growth Fund III. The firm completed 74 investments in 2025 (23 initial and 51 follow-on rounds) and achieved a €24 million real estate exit. Innovestor also operates Energy Storage and Corporate Venturing investment platforms.
Khosla Ventures is a venture capital firm investing across consumer and retail, enterprise, fintech, frontier technologies, sustainability, digital health, medtech and diagnostics, and therapeutics sectors.